eligibility_summary
Recipients: 18-50 with SCD plus ≥1 severe complication (stroke/deficit, frequent ACS/VOCs, chronic transfusions ≥8/yr, PH/TRJV≥2.7, CKD/dialysis, recurrent tricorporal priapism), not pregnant, adequate heart/lung/liver function without cirrhosis/hepatitis. Donor: 12/12 or ≤1-mismatch URD, or haplo related. Exclude: severe organ disease, recent stroke, KPS<50, HIV/active infection, noncompliance/understanding issues, donor-specific antibodies. Donors: consented, HIV/hepatitis−, not pregnant, HbS<50%, CD34≥5×10^6/kg.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions and mechanisms: Siplizumab (TCD601), an anti‑CD2 monoclonal antibody, used for in vivo T‑cell depletion before/around allogeneic HSCT to prevent GVHD and graft failure. Co‑interventions: exchange transfusion (reduces HbS <20% to prevent VOC), low‑dose total body irradiation (2 Gy, lymphodepletion), stem‑cell infusion, post‑transplant cyclophosphamide (50 mg/kg days +3/+4, alkylating agent killing proliferating alloreactive T cells), mesna (uroprotectant binding acrolein), sirolimus (mTOR inhibitor blocking IL‑2–driven T‑cell proliferation), rituximab or biosimilar (anti‑CD20 monoclonal antibody depleting B cells). Targets/pathways: CD2+ T cells/NK cells, alloreactive T cells, mTOR pathway in T cells, CD20+ B cells/antibody responses, globally dividing lymphocytes (alkylation) and lymphoid compartments (TBI), reduction of sickled RBC burden (exchange).